» Articles » PMID: 18199558

Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and Radioresistance

Overview
Journal Cancer Res
Specialty Oncology
Date 2008 Jan 18
PMID 18199558
Citations 142
Authors
Affiliations
Soon will be listed here.
Abstract

Hypoxic and/or anoxic tumor cells can have increased rates of mutagenesis and altered DNA repair protein expression. Yet very little is known regarding the functional consequences of any hypoxia-induced changes in the expression of proteins involved in DNA double-strand break repair. We have developed a unique hypoxic model system using H1299 cells expressing an integrated direct repeat green fluorescent protein (DR-GFP) homologous recombination (HR) reporter system to study HR under prolonged chronic hypoxia (up to 72 h under 0.2% O(2)) without bias from altered proliferation, cell cycle checkpoint activation, or severe cell toxicity. We observed decreased expression of HR proteins due to a novel mechanism involving decreased HR protein synthesis. Error-free HR was suppressed 3-fold under 0.2% O(2) as measured by the DR-GFP reporter system. This decrease in functional HR resulted in increased sensitivity to the DNA cross-linking agents mitomycin C and cisplatin but not to the microtubule-interfering agent, paclitaxel. Chronically hypoxic H1299 cells that had decreased functional HR were relatively radiosensitive [oxygen enhancement ratio (OER), 1.37] when compared with acutely hypoxic or anoxic cells (OER, 1.96-2.61). Using CAPAN1 cells isogenic for BRCA2 and siRNA to RAD51, we confirmed that the hypoxia-induced radiosensitivity was due to decreased HR capacity. Persistent down-regulation of HR function by the tumor microenvironment could result in low-fidelity DNA repair and have significant implications for response to therapy and genetic instability in human cancers.

Citing Articles

Development of a near-infrared fluorescent probe for the selective detection of severe hypoxia.

Kasai T, Fujita K, Komatsu T, Ueno T, Kojima R, Hanaoka K RSC Chem Biol. 2025; 6(3):449-456.

PMID: 39911856 PMC: 11791654. DOI: 10.1039/d4cb00243a.


Tumour hypoxia in driving genomic instability and tumour evolution.

Suvac A, Ashton J, Bristow R Nat Rev Cancer. 2025; 25(3):167-188.

PMID: 39875616 DOI: 10.1038/s41568-024-00781-9.


Engineered Cell Microenvironments: A Benchmark Tool for Radiobiology.

Akolawala Q, Accardo A ACS Appl Mater Interfaces. 2025; 17(4):5563-5577.

PMID: 39813590 PMC: 11788991. DOI: 10.1021/acsami.4c20455.


Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research.

Sharma R, Yadav J, Bhat S, Musayev A, Myrzagulova S, Sharma D Mol Neurobiol. 2025; .

PMID: 39804528 DOI: 10.1007/s12035-024-04680-w.


Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.

Jain A, Barge A, Parris C Oncogene. 2024; 44(4):193-207.

PMID: 39572842 PMC: 11746151. DOI: 10.1038/s41388-024-03227-6.